Treatment and outcomes in classic Hodgkin lymphoma post‐transplant lymphoproliferative disorder in children

Abstract

Classic Hodgkin lymphoma post‐transplant lymphoproliferative disorder (HL‐PTLD) has been rarely reported in children, with limited data available to guide treatment decisions. We report a retrospective review of five children diagnosed with classic HL‐PTLD following solid organ transplant between 2007 and 2013 at Stanford University. Patients were treated with Stanford V chemotherapy and involved field radiation therapy. With a median follow‐up of 7.2 years (range, 4.7–10.5 years) since diagnosis, all patients remain in remission from HL‐PTLD and free from graft failure. In this series, combined modality therapy with risk‐adapted chemotherapy and radiation therapy was a successful strategy for the treatment of classic HL‐PTLD.

Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature

“…However, a recent comparative study analysis between HL-PTLD after SOT and general HL adult patients suggested HL-specific chemotherapy regimens improved overall survival and chemotherapy-related toxicities were not significantly different among the 2 groups 4. Another study did report higher incidence of febrile neutropenia and infectious complications in HL-PTLD after SOT pediatric patients 11. Thus, because of therapy-related toxicities, chemotherapy dose modification was common in patients with CHL-PTLD.…”

“…4 Another study did report higher incidence of febrile neutropenia and infectious complications in HL-PTLD after SOT pediatric patients. 11 Thus, because of therapy-related toxicities, chemotherapy dose modification was common in patients with CHL-PTLD. Some therapyrelated toxicities reported were grade III-IV neutropenia, myelosuppression and sepsis with 2-to 5-year event free survival shown to be 80% 12 (Table 1).…”

Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation

“…T-cell lymphomas do not respond to rituximab and should be treated according to their pathology. Patients with classic Hodgkin lymphoma-like PTLD (the least frequent type of PTLD) should be treated according to the treatment standards of Hodgkin-lymphomas (112)(113)(114).…”